Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.

Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, Davies BR.

Int J Oncol. 2015 Aug;47(2):446-54. doi: 10.3892/ijo.2015.3062. Epub 2015 Jun 22.

2.

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ.

Int J Oncol. 2011 Jul;39(1):271-8. doi: 10.3892/ijo.2011.1022. Epub 2011 Apr 29.

PMID:
21537841
3.

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.

4.

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C.

Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6.

5.

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jürgensmeier JM, Wedge SR, Barry ST.

Mol Cancer Ther. 2007 Aug;6(8):2198-208.

6.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.

7.

PPAR alpha and the regulation of cell division and apoptosis.

Roberts RA, Chevalier S, Hasmall SC, James NH, Cosulich SC, Macdonald N.

Toxicology. 2002 Dec 27;181-182:167-70. Review.

PMID:
12505304
8.

Role of cytokines in non-genotoxic hepatocarcinogenesis: cause or effect?

Roberts RA, James NH, Cosulich S, Hasmall SC, Orphanides G.

Toxicol Lett. 2001 Mar 31;120(1-3):301-6. Review.

PMID:
11323188
9.

Identification of a possible association between carbon tetrachloride-induced hepatotoxicity and interleukin-8 expression.

Holden PR, James NH, Brooks AN, Roberts RA, Kimber I, Pennie WD.

J Biochem Mol Toxicol. 2000;14(5):283-90.

PMID:
10970000
10.

A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopin.

Cosulich SC, James NH, Needham MR, Newham PP, Bundell KR, Roberts RA.

Carcinogenesis. 2000 Sep;21(9):1757-60.

PMID:
10964109
12.

Tumour necrosis factor alpha (TNFalpha): role in suppression of apoptosis by the peroxisome proliferator nafenopin.

Holden PR, Hasmall SC, James NH, West DR, Brindle RD, Gonzalez FJ, Peters JM, Roberts RA.

Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):29-39.

PMID:
10726969
13.

Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha.

Hasmall SC, James NH, Macdonald N, Gonzalez FJ, Peters JM, Roberts RA.

Mutat Res. 2000 Mar 17;448(2):193-200.

PMID:
10725472
14.

Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARalpha.

Roberts RA, James NH, Hasmall SC, Holden PR, Lambe K, Macdonald N, West D, Woodyatt NJ, Whitcome D.

Toxicol Lett. 2000 Mar 15;112-113:49-57. Review.

PMID:
10720712
16.
17.

Role for tumor necrosis factor alpha receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin.

West DA, James NH, Cosulich SC, Holden PR, Brindle R, Rolfe M, Roberts RA.

Hepatology. 1999 Dec;30(6):1417-24.

PMID:
10573520
18.

Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis.

James NH, Gill JH, Brindle R, Woodyatt NJ, Macdonald N, Rolfe M, Hasmall SC, Tugwood JD, Holden PR, Roberts RA.

Toxicol Lett. 1998 Dec 28;102-103:91-6. Review.

PMID:
10022238
20.
22.
23.

Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha).

Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD.

Carcinogenesis. 1998 Jan;19(1):43-8.

PMID:
9472691
26.

Dosing-induced stress causes hepatocyte apoptosis in rats primed by the rodent nongenotoxic hepatocarcinogen cyproterone acetate.

Roberts RA, Soames AR, James NH, Gill JH, Wheeldon EB.

Toxicol Appl Pharmacol. 1995 Dec;135(2):192-9.

PMID:
8545827
27.

Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations.

Roberts RA, Soames AR, Gill JH, James NH, Wheeldon EB.

Carcinogenesis. 1995 Aug;16(8):1693-8.

PMID:
7634391
28.
30.

Quantitation of apoptotic bodies in rat liver by in situ end labelling (ISEL): correlation with morphology.

Wheeldon EB, Williams SM, Soames AR, James NH, Roberts RA.

Toxicol Pathol. 1995 May-Jun;23(3):410-5.

PMID:
7659962
32.

An in vitro model of rodent nongenotoxic hepatocarcinogenesis.

James NH, Molloy CA, Soames AR, French NJ, Roberts RA.

Exp Cell Res. 1992 Dec;203(2):407-19.

PMID:
1281111

Supplemental Content

Loading ...
Support Center